- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01772251
Safety and Tolerability of Oshadi Icp In Patients With Type 1 Diabetes Mellitus - Phase Ib Clinical Study
A Single-Center, Multiple-dose, Randomized, Cross-Over, Double-Blind, Placebo-Controlled Study to Evaluate the Pharmacodynamics, Safety, and Tolerability of Oshadi Icp In Patients With Type 1 Diabetes Mellitus - Phase Ib Clinical Study
Diabetes mellitus (DM) is a chronic disease of carbohydrate, fat, and protein metabolism caused by an absolute or relative deficiency of insulin, an anabolic hormone. The current methods of insulin therapy for diabetic patients are multiple daily injection therapy and continuous subcutaneous insulin infusion with an external pump. This rout of administration may lead to hyperinsulinemia as insulin is administered in a non physiological way, targeting mainly extra hepatic tissues (muscle, fat).
A method of providing insulin without the need for injections has been a goal in drug delivery.
Oshadi Drug Administration Ltd. has developed oral carrier for proteins based on biochemistry and quantum theory of biochemical reactions. The carrier enables the absorption of proteins from the gastrointestinal tract in their full structure. Oshadi has also developed the Oshadi Icp - insulin, proinsulin and C-peptide in Oshadi carrier, administrated orally. This study was design in order to evaluate the safety and feasibility of multiple administration of Oshadi Icp
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Zerifin, Israel
- Assaf-Harofeh Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Type 1 diabetes mellitus (according to ADA criteria) for more than 1 year.
- Male/female 18 years old and older.
- BMI≥18.5 and ≤25
- Female of childbearing age must commit to avoid pregnancy and use contraception during the study.
- Patients must understand and be willing to give written informed consent prior to any study procedures or evaluations and be willing to adhere to all study schedules and requirements.
Exclusion Criteria:
- Any history of significant cardiac, renal, neurologic, metabolic, pulmonary, gastrointestinal, hematologic abnormality, chronic hepatic disease or any other disease which in the judgment of the investigator would interfere with the study or confound the results.
- Symptomatic DKA in the last 6 months
- Patients with positive HIV or HCV serology or positive HBsAg at screening.
- History or evidence of any active liver disease.
- History of epilepsy.
- One hypoglycemic seizure episode in the last six months or more than one hypoglycemic seizure episode in the last year.
- History of sever recurrent hypoglycemic unawareness.
- C-peptide >3 mg/ml (fasting)
- Total average daily insulin dosage ≥1 IU/kg of body weight.
- Polycystic ovary syndrome
- Acanthosis nigricans
- 6.5% > HbA1c or HbA1c >10%
- eGFR<60.
- Female patients who are breastfeeding or have a positive pregnancy test at screening or at any time during the study and not willing to practice birth control during study period.
- Inability to give written informed consent
- History of alcohol or drug abuse within 6 months of screening.
- Patients who have a positive urine drug screen for substances of abuse (benzodiazepine, THC, opiates, amphetamines, cocaine) at the screening.
- Mental disorders.
- Patients with poor venous access
- Significant swallowing disorders
- Digestive disorders
- Small bowel surgery
- Any intercurrent disease during the last week prior to screening which in the judgment of the investigator might affect blood glucose level.
- Any infectious disease developed during the 4 weeks prior to the study.
- Malabsorption disorders.
- Any significant abnormality by principal investigator in the baseline laboratory evaluation: liver and kidney functions, electrolytes, albumin, lipase, TSH, hemoglobin, white blood cell count and differential, platelets.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Oshadi Icp & placebo
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Adverse events and serious adverse events occurence
Time Frame: last follow-up visit (day 23)
|
last follow-up visit (day 23)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
• To assess the pharmacodynamic effect of multiple doses of Oshadi Icp as measured by the area under the glucose concentration-time curve
Time Frame: last administration day (day 17)
|
last administration day (day 17)
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
• Evaluating the total daily injected insulin dose during administration of Oshadi Icp vs. placebo
Time Frame: Last administration day (day 17)
|
Last administration day (day 17)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- OS-ICP-P1b-01
- 2012-004270-26 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Insulin-Dependent, 1
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
University of California, San FranciscoJuvenile Diabetes Research FoundationCompletedType 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMUnited States, Australia
-
Stanford UniversityConvaTec Inc.CompletedInsulin Dependent Diabetes Mellitus 1United States
-
Samsung Medical CenterMinistry of Trade, Industry & Energy, Republic of Korea; Korea Evaluation Institute... and other collaboratorsCompletedDiabetes Mellitus | Insulin-dependent Diabetes Mellitus | Insulin HypoglycemiaKorea, Republic of
-
DreaMed DiabetesCompletedDiabetes Mellitus, Type 1 | Insulin-dependent Diabetes MellitusIsrael
-
National Institute of Diabetes and Digestive and...Completed
-
Xeris PharmaceuticalsCompletedDiabetes Mellitus, Type 1 | Insulin-dependent Diabetes MellitusUnited States
-
Wayne State UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Insulin DependentUnited States
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)CompletedDiabetes Mellitus | Insulin-dependent Diabetes MellitusUnited States
-
The University of Texas Health Science Center,...National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
Clinical Trials on Oshadi Icp
-
Oshadi Drug AdministrationCompletedDiabetes Mellitus | Insulin-Dependent | Type 1Israel
-
Oshadi Drug AdministrationCompleted
-
Oshadi Drug AdministrationCompletedCancer | Metastasis | TumorIsrael
-
Oshadi Drug AdministrationSuspended
-
Oshadi Drug AdministrationCompletedLupus Erythematosus, SystemicIsrael
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingModerate to Severe Atopic DermatitisChina
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingModerate to Severe Plaque PsoriasisChina
-
Oshadi Drug AdministrationUnknownCarcinoma, Non-Small-Cell LungIsrael
-
University of MichiganMedical University of South Carolina; University of Pennsylvania; National Institute... and other collaboratorsRecruitingBrain Injuries, TraumaticUnited States, Canada
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingIntrahepatic Cholangiocarcinoma (ICC)China